Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an open-market sale of 30,593 shares of common stock at a weighted average price of $14.08 per share on March 11, 2026. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance. Following the sale, Lo directly holds 291,374 shares of Adaptive Biotechnologies common stock and has an additional 2,500 shares held indirectly through a spouse. The sale price range for the trades was between $13.81 and $14.38 per share.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 41,338 shares of common stock on March 11, 2026 at an average price of $13.17 per share. According to the disclosure, this transaction was required to cover tax withholding obligations related to vesting restricted stock units and was executed under a mandatory “sell to cover” election, meaning it was not a discretionary trade. Following the sale, Bobulsky directly holds 427,775 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benz eno, reported an open-market sale of 63,103 shares of common stock at $13.17 per share. After the transaction, she directly holds 272,751 shares.
The company’s equity plan required this sale to cover tax withholding on vested restricted stock units, so it was a mandated “sell-to-cover” transaction rather than a discretionary trade.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported a mandated sale of 18,672 shares of Common Stock on March 11, 2026. The shares were sold at an average price of $13.17 per share and were executed as an open-market transaction.
According to the disclosure, this sale was required to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The footnote states the transaction was a “sell to cover” and not a discretionary trade by Piskel. After the sale, he directly holds 259,840 shares of Adaptive Biotechnologies Corp common stock.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported selling a total of 470,266 shares of common stock on March 11, 2026 at $13.17 per share. According to the footnotes, both sales were mandated "sell to cover" transactions to satisfy tax withholding on vesting RSUs and performance share units, and did not represent discretionary trading decisions. After these transactions, Robins directly owned 1,522,058 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported mandated share sales tied to equity award vesting. On March 11, 2026, he sold a total of 470,167 shares of Common Stock at $13.17 per share in open-market transactions.
Footnotes explain these sales were required to cover tax withholding obligations from vesting RSUs and performance share units under the company’s equity incentive plans, and they were not discretionary trades. After these transactions, Robins directly holds 2,301,113 shares of Adaptive Biotechnologies Common Stock.
ADPT insider filing: proposed resale of Common Stock by Francis Lo under Rule 144 and 10b5-1 plan. The filing lists multiple recent sales by Francis Lo, including 38,074 shares on 03/05/2026 for $574,536.66 and earlier 10b5-1 sales of 79,590 shares on 01/12/2026 for $1,411,393.35. The record also lists 30,593 Restricted Stock Units dated 03/04/2025.
Michelle Griffin reported sales of Common Stock. The filing shows Ms. Griffin disposed of 48,044 shares on 03/03/2026 for $735,299.01. The form also lists 15,394 restricted shares associated with Morgan Stanley Smith Barney LLC dated 03/04/2026.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an exercise-and-sell trading pattern in March 2026. She exercised stock options for a total of 68,328 shares of Common Stock at exercise prices of $6.55 and $12.14 per share, then sold 81,342 shares in open-market transactions.
The sales occurred on March 6, 9 and 10, 2026 at weighted-average prices including $15.14, $14.79 and $14.68 per share. All transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 643,471 shares of Common Stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice registering 38,074 shares of Common stock to be sold, labeled as RSUs with an effective date of 03/04/2026.
The filing also lists recent 10b5-1 sales attributable to Francis Lo, including 79,590 shares on 01/12/2026 and 3,125 shares on 01/02/2026.